The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
Top Cited Papers
- 1 December 2007
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (12) , 2368-2375
- https://doi.org/10.1111/j.1538-7836.2007.02764.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effects of the Factor Xa Inhibitor Apixaban on Venous Thrombosis and Hemostasis in Rabbits.Blood, 2006
- Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.Blood, 2006
- In Vitro Evaluation of Apixaban, a Novel, Potent, Selective and Orally Bioavailable Factor Xa Inhibitor.Blood, 2006
- Incidence and Timing of Myocardial Infarction After Total Joint ArthroplastyThe Journal of Arthroplasty, 2006
- When Heparins Promote ThrombosisCirculation, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Frequency of Myocardial Infarction, Pulmonary Embolism, Deep Venous Thrombosis, and Death following Primary Hip or Knee ArthroplastyAnesthesiology, 2002
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972